(Q36316698)

13 August 2017

1 reference

title

Pegylated IFNs for chronic hepatitis C: an update (English)

1 reference

13 August 2017

1 reference

1 reference

Michael J Grace

1

1 reference

13 August 2017

David L Cutler

series ordinal

2

1 reference

13 August 2017

Ronald W Bordens

series ordinal

3

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Expert Opinion on Drug Delivery

13 August 2017

1 reference

13 August 2017

2

1 reference

13 August 2017

2

1 reference

13 August 2017

219-226

1 reference

Hepatitis C virus infection

13 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Clinical Pharmacokinetics of Interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Pegylation: a novel process for modifying pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Structural and biologic characterization of pegylated recombinant IFN-alpha2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Pegylated interferons for the treatment of chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Structure, biology, and therapeutic implications of pegylated interferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.2.219

21 January 2018

Identifiers

DOI

10.1517/17425247.2.2.219

1 reference

13 August 2017

1 reference